1. Barré-Sinoussi, F., Chermann, J. C., Rey, F., Nugeyre, M. T., Chamaret, S., Gruest, J., Dauguet, C., Axler-Blin, C., Vézinet-Brun, F., Rouzioux, C., Rozenbaum, W., & Montagnier, L. (1983). Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science (New York N Y), 220(4599), 868–871. https://doi.org/10.1126/science.6189183.
2. FDA Approves Drug for HIV Prevention. (2019, May 15). Center for Disease Control and Prevention. https://www.cdc.gov/nchhstp/newsroom/2012/fda-approvesdrugstatement.html.
3. Priority Jurisdictions (2020, November 3). : Phase I. HIV.gov. https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/jurisdictions/phase-one.
4. HIV in the United States by Region: HIV Incidence. (2022, May 3). Centers for Disease Control and Prevention. https://www.cdc.gov/hiv/statistics/overview/incidence.html.
5. Statistics, U. S. (2021, June 2). HIV.gov. https://www.hiv.gov/hiv-basics/overview/data-and-trends/statistics.